# Elucidating the biosynthesis of mycofactocin, an unknown molecule essential for M. tuberculosis

> **NIH NIH R01** · UNIVERSITY OF DENVER (COLORADO SEMINARY) · 2021 · $286,351

## Abstract

PROJECT SUMMARY
Mycobacterium tuberculosis (Mtb), the world’s deadliest disease, affects an estimated one-third of the world’s
population. There is an urgent need to deepen our understanding of Mtb physiology so that new drug targets
can be identified and exploited, thereby resulting in improved human health. Mtb has evolved to utilize the host’s
cholesterol as a main carbon source when enveloped by the macrophage, increasing its persistence and
pathogenicity. The genes mftC, mftD, and mftE were shown to be critical for Mtb growth on cholesterol and
belong to the mycofactocin biosynthetic pathway, which is encoded by the gene cluster mftABCDE. Mycofactocin
has been proposed to be a novel, peptide-derived, redox cofactor, however the final structure and physiological
role of the molecule has yet to be determined. It is known that the first step of mycofactocin biosynthesis begins
with the MftC catalyzed decarboxylation of the conserved C-terminal tyrosine on MftA, assisted by protein
interactions with the peptide chaperone MftB. Characterization of mycofactocin biosynthesis is a straightforward
approach towards evaluating a potentially druggable pathway while advancing our understanding of a critical
component in Mtb physiology and constitutes the long-term goal. The overall objective of this application is to
apply biochemical and biophysical concepts and techniques to study mycofactocin biosynthesis by elucidating
the chemical mechanism of MftC catalysis, resolving the sequences required for protein interactions within the
pathway, and to elucidate the chemistry and the product of MftD catalysis. The central hypothesis is that
mycofactocin is synthesized from extensive modification of the C-terminal tyrosine on MftA by MftC and MftD.
These modifications require fine tuning of the electrochemical environments of the redox centers in MftC, a flavin
dependent reaction catalyzed by MftD, and specific protein-protein and protein-peptide interactions. Considering
that MftC, MftD, and MftE are required for Mtb, leaving the mycofactocin biosynthetic pathway uncharacterized
prevents potentially exploiting them as therapeutic targets for Mtb. Guided by strong preliminary data, the
hypothesis will be tested by the three specific aims: 1) Determine the mechanism of MftC catalyzed oxidative
decarboxylation of MftA, 2) Resolve sequence motifs involved in interactions with the mycofactocin biosynthetic
pathway peptide and peptide chaperone, and 3) Discover the function of MftD in mycofactocin biosynthesis. The
research is innovative, because it departs from the status quo by elucidating the biosynthesis of a potentially
new, peptide derived, redox cofactor and by providing sequence and spatial resolution of the little understood
protein interactions that are required for mycofactocin biosynthesis. Advances made through the characterization
of the mycofactocin biosynthetic pathway will provide valuable information about essential Mtb proteins and will
increase ...

## Key facts

- **NIH application ID:** 10136631
- **Project number:** 5R01GM124002-05
- **Recipient organization:** UNIVERSITY OF DENVER (COLORADO SEMINARY)
- **Principal Investigator:** SANDRA S. EATON
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $286,351
- **Award type:** 5
- **Project period:** 2017-08-15 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10136631

## Citation

> US National Institutes of Health, RePORTER application 10136631, Elucidating the biosynthesis of mycofactocin, an unknown molecule essential for M. tuberculosis (5R01GM124002-05). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10136631. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
